596

PREVALENCE AND IMPACT OF PROTEIN-CALORIE MALNUTRITION IN PATIENTS HOSPITALIZED WITH GASTROINTESTINAL DISORDERS

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

This session would provide attendees with a foundational understanding of the pathophysiology of intestinal failure and short bowel syndrome which inform the management of the disease. Attendees will learn the most up-to-date diet, pharmcologic and surgical therapies for intestinal failure of short bowel syndrome as well as how to prevent and manage long term complications of the disease.
Introduction
Protein-calorie malnutrition (PCM) has been reported in up to 48% of hospitalizations and is associated with adverse clinical outcomes, such as increased length of stay, morbidity, and mortality. PCM is known to be intricately linked with IBD and infections, but the relationship between PCM and various gastrointestinal (GI) disorders is less well defined. The aim of this study was to evaluate the prevalence and impact of PCM in patients hospitalized with different GI conditions.

Methods
The National Inpatient Sample was queried for patients hospitalized with and without GI disorders between 2016 and 2018. GI disorders were identified based on ICD-10 codes in the first 3 diagnosis positions. The prevalence of PCM was compared across patients with different GI disorders and patients without a GI disorder. Multivariable logistic and linear regression were performed to compare death, length of stay and total utilization charges between those with and without PCM, adjusting for age, sex, race, comorbidity index, elective admission, primary payer, zip code income, residence population size, region, hospital size, hospital urban and teaching status.

Results
Amongst 107,001,354 hospitalization events from 2016-2018, there were 8,246,820 (7.7%) patients hospitalized with a GI condition. The prevalence of PCM was highest in those with esophageal dysmotility, Clostridioides difficile infection, cholangitis, infectious gastroenteritis, Crohn’s disease, ulcerative colitis, GI bleed, gastroparesis, chronic pancreatitis, and acute pancreatitis, and had higher prevalence of PCM compared to all combined non-GI disorders (Table 1). Patients with PCM hospitalized for a GI disorder had greater adjusted relative odds of death (OR: 3.09; 95% CI: 2.96-3.22), longer length of stay (4.31; 95% CI 4.21-4.40), and higher total charges (38788.14; 95% CI: 37303.79-40272.49) compared to those without PCM (Table 2).

Conclusion
Our study found increased utilization metrics amongst all patients hospitalized for a GI disorder with PCM, with increased relative mortality, length of stay, and total charges. GI disorders that impact motility and ability to tolerate oral intake, such as esophageal motility and gastroparesis, had increased PCM prevalence. Inflammatory disorders, including all infection types, IBD and pancreatitis also had rates of PCM greater than those hospitalized without a GI disorder, potentially due to increased catabolism and poor nutrition in these states. Our findings highlight the importance of early recognition and treatment of PCM in these specific GI conditions given the increased utilization burden seen in these patients.

Tracks

Related Products

Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for RATES OF SURGERY FOR STRICTURING CROHN'S DISEASE IN THE BIOLOGIC ERA
RATES OF SURGERY FOR STRICTURING CROHN'S DISEASE IN THE BIOLOGIC ERA
LUNCH AND TRAINEE JEOPARDY! 12:00 PM - 1:00 PM LEADERSHIP FORUM, NETWORKING SESSION AND ROUNDTABLES 4:00 PM - 5:30 PM KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY 4:00 PM - 4:30 PM
Thumbnail for RATES OF SURGERY FOR STRICTURING CROHN'S DISEASE IN THE BIOLOGIC ERA
RATES OF SURGERY FOR STRICTURING CROHN'S DISEASE IN THE BIOLOGIC ERA
BACKGROUND: Local excision (LE) with transanal endoscopic microsurgery (TEM) is an established alternative to radical resection in select early rectal cancers and high-risk patients…